Reference number
1698-H

SPECIALTY QUANTITY LIMIT PROGRAM

LENVIMA (lenvatinib mesylate)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications and medullary thyroid carcinoma fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	Standard Limit*	FDA-recommended dosing
Lenvima 4 mg 30-day dose carton	1 carton (30 capsules total) per 30 days	Differentiated thyroid cancer: 24 mg per day Renal cell carcinoma: 18 mg per day Hepatocellular carcinoma: 8 mg per day for patients less than 60 kg; 12 mg per day for patients greater than or equal to 60 kg Endometrial carcinoma: 20 mg per day Dose reductions may be required after adverse events or in patients with severe renal or hepatic impairment.
Lenvima 8 mg 30-day dose carton	1 carton (60 capsules total) per 30 days	
Lenvima 10 mg 30-day dose carton	1 carton (30 capsules total) per 30 days	
Lenvima 12 mg 30-day dose carton	1 carton (90 capsules total) per 30 days	
Lenvima 14 mg 30-day dose carton	1 carton (60 capsules total) per 30 days	
Lenvima 18 mg 30-day dose carton	1 carton (90 capsules total) per 30 days	
Lenvima 20 mg 30-day dose carton	1 carton (60 capsules total) per 30 days	
Lenvima 24 mg 30-day dose carton	1 carton (90 capsules total) per 30 days	

*Lenvima is available in 4 mg and 10 mg capsules. These are packed in cards in various combinations to obtain the desired dose.

III. REFERENCE

1. Lenvima [package insert]. Woodcliff Lake, NJ: Eisai, Inc.; September 2019.

CVS caremark™